Meta‐analysis of immune‐related adverse events of immune checkpoint inhibitor therapy in cancer patients

BACKGROUND: Immune checkpoint inhibitors (ICIs) have significant clinical efficacy in the treatment of non‐small cell lung cancer (NSCLC); however, the incidence of immune‐related adverse events (irAEs) of up to 50% has prevented their widespread use. With the increase in the use of ICIs alone or as...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Peng, Zhang, Dingding, Cui, Xiaoxia, Zhang, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471041/
https://www.ncbi.nlm.nih.gov/pubmed/32643323
http://dx.doi.org/10.1111/1759-7714.13541

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7471041/
https://www.ncbi.nlm.nih.gov/pubmed/32643323
http://dx.doi.org/10.1111/1759-7714.13541

Ejemplares similares